LONDON, July 13, 2012 (LifeSiteNews.com)— A key talking point of Melinda Gates’ new $4 billion campaign to push birth control on women in Africa, Asia, and Latin America is her claim that there is “no controversy” in contraceptives.
But a new campaign by the international pro-life organization Human Life International aims to show just the opposite.
On HLI’s campaign website, FactsforMelindaGates.com, they lay out key facts showing the dangers of contraception, particularly when used in the Third World without the availability of even basic healthcare.
A cornerstone of Gate’s effort is the development of a new injectable contraceptive equivalent to the currently available medroxyprogesterone acetate also known as DMPA, or by its brand name Depo-Provera.
But Depo-Provera and other hormonal contraceptives are often dangerous to women’s health. They have been known to accelerate the transmission of HIV/AIDS and increase the risk of breast cancer, in addition to other health problems.
“Several types of hormonal contraceptives,” states HLI, “have been labeled Group-1 Carcinogens — the same category as cigarettes and asbestos — by the World Health Organization.”
Gates, along with the British government and the world’s largest abortion providers, including the International Planned Parenthood Foundation and Marie Stopes International, hope to bring contraception to at least an additional 120 million women worldwide, with the primary focus being in sub-Saharan African and South Asia.
According to HLI, not only are the contraceptives dangerous to women’s health, but Marie Stopes International and IPPF were “founded by leaders in the early eugenics and population control movements, and who were very open about the fact that they did not like the idea of poor people of color having children.”
HLI points out that the population control movement began moving towards the language of “equality,” sustainability,” and “reproductive health” at the UN’s 1994 Conference on Population and Development in Cairo, but the tactics remain the same.